{"id":10312,"date":"2025-12-02T22:32:45","date_gmt":"2025-12-02T19:32:45","guid":{"rendered":"https:\/\/www.ortaakarsu.net\/?p=10312"},"modified":"2025-12-02T22:32:45","modified_gmt":"2025-12-02T19:32:45","slug":"sotorasib-nedir-kras-g12c-mutasyonuna-yonelik-kucuk-molekul-hedefe-yonelik-tedavi","status":"publish","type":"post","link":"https:\/\/www.ortaakarsu.net\/?p=10312","title":{"rendered":"Sotorasib Nedir? KRAS G12C Mutasyonuna Y\u00f6nelik K\u00fc\u00e7\u00fck Molek\u00fcl Hedefe Y\u00f6nelik Tedavi"},"content":{"rendered":"<h2>Sotorasib Nedir? K\u00fc\u00e7\u00fck Molek\u00fcl Bir Hedefe Y\u00f6nelik Tedavi Olarak Neden Farkl\u0131?<\/h2>\n<p>Sotorasib, KRAS G12C mutasyonunu spesifik olarak hedefleyen, oral yolla kullan\u0131lan k\u00fc\u00e7\u00fck molek\u00fcl bir inhibit\u00f6rd\u00fcr. KRAS, onkoloji d\u00fcnyas\u0131nda y\u0131llarca \u201cila\u00e7lanamaz\u201d olarak kabul edilen, mutasyona u\u011frad\u0131\u011f\u0131nda h\u00fccreyi s\u00fcrekli b\u00fcy\u00fcme sinyali alt\u0131nda tutan bir onkogen olarak biliniyordu. Sotorasib, bu alg\u0131y\u0131 k\u0131ran ilk k\u00fc\u00e7\u00fck molek\u00fcl ila\u00e7lardan biri olarak, akci\u011fer kanseri tedavisinde yeni bir \u00e7a\u011f\u0131n kap\u0131s\u0131n\u0131 aral\u0131yor <strong>[doi:10.1056\/NEJMoa1917239]<\/strong>.<\/p>\n<p>FDA, sotorasib\u2019i 2021 y\u0131l\u0131nda KRAS G12C mutasyonlu, ileri evre k\u00fc\u00e7\u00fck h\u00fccreli d\u0131\u015f\u0131 akci\u011fer kanseri (NSCLC) hastalar\u0131nda, platin bazl\u0131 kemoterapi ve\/veya imm\u00fcnoterapi sonras\u0131 ikinci basamak tedavi i\u00e7in onaylad\u0131 <strong>[doi:10.1056\/NEJMp2106845]<\/strong>. Yani bu ila\u00e7, klasik kemoterapinin \u00f6tesine ge\u00e7ip, genetik profili tan\u0131mlanm\u0131\u015f hastalarda ki\u015fiselle\u015ftirilmi\u015f tedavinin g\u00fc\u00e7l\u00fc bir temsilcisi haline geldi.<\/p>\n<h2>K\u00fc\u00e7\u00fck Molek\u00fcl Sotorasib Nas\u0131l \u00c7al\u0131\u015f\u0131r? KRAS G12C\u2019yi \u201cKilitleyen\u201d Mekanizma<\/h2>\n<p>KRAS G12C mutasyonu, h\u00fccre i\u00e7i sinyal yollar\u0131n\u0131 s\u00fcrekli \u201ca\u00e7\u0131k\u201d konumda tutarak kontrols\u00fcz h\u00fccre \u00e7o\u011falmas\u0131na yol a\u00e7ar. Normalde KRAS, GTP ba\u011fl\u0131 aktif ve GDP ba\u011fl\u0131 inaktif formlar aras\u0131nda gidip gelir. G12C mutasyonu, bu d\u00f6ng\u00fcy\u00fc bozarak kanser h\u00fccresini adeta \u201cgaz pedal\u0131na tak\u0131l\u0131\u201d b\u0131rak\u0131r.<\/p>\n<p>Sotorasib, k\u00fc\u00e7\u00fck molek\u00fcl yap\u0131s\u0131 sayesinde t\u00fcm\u00f6r h\u00fccresine kolayca girer ve KRAS G12C proteininin inaktif (GDP ba\u011fl\u0131) formundaki mutasyona u\u011fram\u0131\u015f sistein kal\u0131nt\u0131s\u0131na kovalent olarak ba\u011flan\u0131r <strong>[doi:10.1038\/s41586-020-2535-0]<\/strong>. Bu se\u00e7ici ba\u011flanma sonucunda:<\/p>\n<ul>\n<li>KRAS\u2019\u0131n tekrar aktif (GTP ba\u011fl\u0131) forma ge\u00e7mesi engellenir,<\/li>\n<li>RAS\/RAF\/MEK\/ERK sinyal yolu bask\u0131lan\u0131r,<\/li>\n<li>T\u00fcm\u00f6r h\u00fccre proliferasyonu durur ve apoptoz (programl\u0131 h\u00fccre \u00f6l\u00fcm\u00fc) tetiklenir.<\/li>\n<\/ul>\n<p>Bu nedenle sotorasib, molek\u00fcler d\u00fczeyde \u201cs\u00fcrekli a\u00e7\u0131k kalan kanser anahtar\u0131n\u0131 kilitleyen k\u00fc\u00e7\u00fck bir anahtar\u201d gibi davran\u0131r. K\u00fc\u00e7\u00fck molek\u00fcl olmas\u0131, hedef proteinin dar cebi (binding pocket) i\u00e7ine tam oturmas\u0131n\u0131 ve y\u00fcksek \u00f6zg\u00fcll\u00fckle ba\u011flanmas\u0131n\u0131 m\u00fcmk\u00fcn k\u0131lar.<\/p>\n<h2>Klinik Veriler: Sotorasib Ger\u00e7ek Hastalarda Ne Kadar Etkili?<\/h2>\n<p><strong>CodeBreaK 100<\/strong> faz 2 \u00e7al\u0131\u015fmas\u0131, daha \u00f6nce sistemik tedavi alm\u0131\u015f KRAS G12C pozitif NSCLC hastalar\u0131nda y\u00fcr\u00fct\u00fcld\u00fc. Bu \u00e7al\u0131\u015fmada:<\/p>\n<ul>\n<li><strong>Objektif yan\u0131t oran\u0131 (ORR):<\/strong> Yakla\u015f\u0131k %37,<\/li>\n<li><strong>Hastal\u0131k kontrol oran\u0131:<\/strong> Yakla\u015f\u0131k %80,<\/li>\n<li><strong>Medyan progresyonsuz sa\u011fkal\u0131m (PFS):<\/strong> 6,8 ay,<\/li>\n<li><strong>Medyan genel sa\u011fkal\u0131m (OS):<\/strong> 12,5 ay civar\u0131nda bildirildi <strong>[doi:10.1056\/NEJMoa2103695]<\/strong>.<\/li>\n<\/ul>\n<p>Bu rakamlar, yo\u011fun \u015fekilde tedavi g\u00f6rm\u00fc\u015f ve s\u0131n\u0131rl\u0131 se\u00e7ene\u011fi kalan bir hasta grubunda, k\u00fc\u00e7\u00fck molek\u00fcl bir ilac\u0131n ne kadar anlaml\u0131 klinik fayda sa\u011flayabildi\u011fini g\u00f6steriyor. \u00d6zellikle kemoterapi sonras\u0131 progresyon g\u00f6steren hastalarda, sotorasib ile t\u00fcm\u00f6r y\u00fck\u00fcnde belirgin k\u00fc\u00e7\u00fclmeler ve semptomlarda iyile\u015fme rapor edildi <strong>[doi:10.1016\/S1470-2045(21)00152-3]<\/strong>.<\/p>\n<h2>Sotorasib\u2019in Yan Etkileri: K\u00fc\u00e7\u00fck Molek\u00fcl, Y\u00f6netilebilir Toksisite<\/h2>\n<p>Sotorasib, klasik sitotoksik kemoterapilere k\u0131yasla daha hedefe y\u00f6nelik \u00e7al\u0131\u015ft\u0131\u011f\u0131 i\u00e7in, yan etki profili genellikle daha y\u00f6netilebilir kabul ediliyor. En s\u0131k bildirilen yan etkiler \u015funlar:<\/p>\n<ul>\n<li>Diyare,<\/li>\n<li>Bulant\u0131 ve kusma,<\/li>\n<li>Yorgunluk,<\/li>\n<li>Karaci\u011fer enzimlerinde (ALT\/AST) y\u00fckselme <strong>[doi:10.1016\/S1470-2045(21)00152-3]<\/strong>.<\/li>\n<\/ul>\n<p>Yan etkilerin b\u00fcy\u00fck b\u00f6l\u00fcm\u00fc hafif\u2013orta \u015fiddette olup, doz ayarlamas\u0131, ge\u00e7ici ila\u00e7 kesilmesi veya destek tedavilerle kontrol alt\u0131na al\u0131nabiliyor. Bu da sotorasib\u2019i, uzun s\u00fcreli kullan\u0131m i\u00e7in g\u00f6rece uygun bir k\u00fc\u00e7\u00fck molek\u00fcl hedefe y\u00f6nelik tedavi se\u00e7ene\u011fi haline getiriyor.<\/p>\n<h2>Ki\u015fiselle\u015ftirilmi\u015f T\u0131p D\u00f6nemi: Sotorasib Kullan\u0131m\u0131 \u0130\u00e7in KRAS G12C Testi \u015eart<\/h2>\n<p>Sotorasib, yaln\u0131zca KRAS G12C mutasyonu ta\u015f\u0131yan t\u00fcm\u00f6rlerde etkili oldu\u011fundan, tedavi \u00f6ncesinde mutlaka molek\u00fcler test yap\u0131lmas\u0131 gerekiyor. Bu ama\u00e7la:<\/p>\n<ul>\n<li>T\u00fcm\u00f6r biyopsisinde <strong>Next-Generation Sequencing (NGS)<\/strong> panelleri,<\/li>\n<li><strong>S\u0131v\u0131 biyopsi<\/strong> ile dola\u015f\u0131mdaki t\u00fcm\u00f6r DNA\u2019s\u0131 (ctDNA) analizi<\/li>\n<\/ul>\n<p>kullan\u0131labiliyor <strong>[doi:10.1038\/s41571-021-00516-7]<\/strong>. B\u00f6ylece sotorasib, yaln\u0131zca ger\u00e7ekten fayda g\u00f6rmesi beklenen hasta grubuna veriliyor ve ki\u015fiselle\u015ftirilmi\u015f tedavi yakla\u015f\u0131m\u0131 g\u00fc\u00e7leniyor. Bu, k\u00fc\u00e7\u00fck molek\u00fcl ila\u00e7lar\u0131n genetik teste dayal\u0131 se\u00e7imi a\u00e7\u0131s\u0131ndan da \u00f6nemli bir paradigma de\u011fi\u015fimi.<\/p>\n<h2>Diren\u00e7 ve Gelecek: Kombinasyon Stratejileri Neden G\u00fcndemde?<\/h2>\n<p>Ne yaz\u0131k ki, bir\u00e7ok hedefe y\u00f6nelik tedavide oldu\u011fu gibi sotorasib\u2019e kar\u015f\u0131 da zamanla diren\u00e7 geli\u015febiliyor. Diren\u00e7 mekanizmalar\u0131 aras\u0131nda:<\/p>\n<ul>\n<li>KRAS \u00fczerinde yeni mutasyonlar\u0131n ortaya \u00e7\u0131kmas\u0131,<\/li>\n<li>Alternatif sinyal yollar\u0131n\u0131n (\u00f6rne\u011fin PI3K, MET) aktive olmas\u0131,<\/li>\n<li>T\u00fcm\u00f6r mikro\u00e7evresinde imm\u00fcn ka\u00e7\u0131\u015f mekanizmalar\u0131n\u0131n g\u00fc\u00e7lenmesi<\/li>\n<\/ul>\n<p>gibi fakt\u00f6rler yer al\u0131yor <strong>[doi:10.1038\/s41586-021-04064-x]<\/strong>. Bu nedenle g\u00fcncel ara\u015ft\u0131rmalar, sotorasib\u2019in a\u015fa\u011f\u0131daki ila\u00e7larla kombinasyonunu inceliyor:<\/p>\n<ul>\n<li><strong>MEK inhibit\u00f6rleri<\/strong> ile sinyal yolunu daha derin bask\u0131lama,<\/li>\n<li><strong>PD-1\/PD-L1 imm\u00fcnoterapileri<\/strong> ile ba\u011f\u0131\u015f\u0131kl\u0131k sistemini yeniden aktive etme,<\/li>\n<li><strong>SHP2 inhibit\u00f6rleri<\/strong> ile upstream RAS sinyalini kesme.<\/li>\n<\/ul>\n<p>Bu kombinasyon stratejileri, hem yan\u0131t oran\u0131n\u0131 art\u0131rmay\u0131 hem de yan\u0131t s\u00fcresini uzatmay\u0131 hedefliyor. K\u0131sacas\u0131, sotorasib yaln\u0131zca tek ba\u015f\u0131na bir \u201ck\u00fc\u00e7\u00fck molek\u00fcl y\u0131ld\u0131z\u201d de\u011fil, ayn\u0131 zamanda gelece\u011fin kombinasyon tedavilerinin merkez oyuncular\u0131ndan biri olmaya aday.<\/p>\n<h2>S\u0131k Sorulan Sorular (SSS)<\/h2>\n<h3>1. Sotorasib hangi kanser t\u00fcrlerinde kullan\u0131l\u0131yor?<\/h3>\n<p>Sotorasib g\u00fcncel olarak esas olarak <strong>KRAS G12C mutasyonlu, ileri evre k\u00fc\u00e7\u00fck h\u00fccreli d\u0131\u015f\u0131 akci\u011fer kanseri (NSCLC)<\/strong> tedavisinde, platin bazl\u0131 kemoterapi ve\/veya imm\u00fcnoterapi sonras\u0131 ikinci basamakta kullan\u0131l\u0131yor. Kolorektal kanser ve di\u011fer solid t\u00fcm\u00f6rlerde de klinik \u00e7al\u0131\u015fmalar devam ediyor <strong>[doi:10.1056\/NEJMoa2103695]<\/strong>.<\/p>\n<h3>2. Sotorasib klasik kemoterapi mi, yoksa hedefe y\u00f6nelik bir ila\u00e7 m\u0131?<\/h3>\n<p>Sotorasib, <strong>hedefe y\u00f6nelik k\u00fc\u00e7\u00fck molek\u00fcl bir KRAS G12C inhibit\u00f6r\u00fcd\u00fcr<\/strong>. Klasik kemoterapi gibi h\u0131zl\u0131 b\u00f6l\u00fcnen t\u00fcm h\u00fccreleri \u00f6ld\u00fcrmek yerine, yaln\u0131zca KRAS G12C mutasyonlu t\u00fcm\u00f6r h\u00fccrelerinin b\u00fcy\u00fcme sinyalini kesmeyi ama\u00e7lar <strong>[doi:10.1056\/NEJMoa1917239]<\/strong>.<\/p>\n<h3>3. Sotorasib nas\u0131l kullan\u0131l\u0131yor? Tablet mi, serum mu?<\/h3>\n<p>Sotorasib, <strong>oral yolla al\u0131nan tablet formunda<\/strong> bir k\u00fc\u00e7\u00fck molek\u00fcl ila\u00e7t\u0131r. Damar i\u00e7i inf\u00fczyon gerektirmemesi, hastalar i\u00e7in kullan\u0131m kolayl\u0131\u011f\u0131 ve ya\u015fam kalitesi a\u00e7\u0131s\u0131ndan \u00f6nemli bir avantaj sa\u011flar <strong>[doi:10.1056\/NEJMp2106845]<\/strong>.<\/p>\n<h3>4. Sotorasib\u2019in en s\u0131k g\u00f6r\u00fclen yan etkileri nelerdir?<\/h3>\n<p>En s\u0131k bildirilen yan etkiler aras\u0131nda <strong>diyare, bulant\u0131, yorgunluk ve karaci\u011fer enzimlerinde y\u00fckselme<\/strong> bulunur. \u00c7o\u011fu yan etki hafif\u2013orta d\u00fczeydedir ve doz ayarlamas\u0131 veya destek tedavilerle y\u00f6netilebilir <strong>[doi:10.1016\/S1470-2045(21)00152-3]<\/strong>.<\/p>\n<h3>5. Sotorasib her KRAS mutasyonu i\u00e7in etkili midir?<\/h3>\n<p>Hay\u0131r. Sotorasib, <strong>\u00f6zellikle KRAS G12C mutasyonunu<\/strong> hedeflemek \u00fczere tasarlanm\u0131\u015f bir k\u00fc\u00e7\u00fck molek\u00fcl inhibit\u00f6rd\u00fcr. G12D, G13D gibi di\u011fer KRAS mutasyonlar\u0131 i\u00e7in farkl\u0131 deneysel k\u00fc\u00e7\u00fck molek\u00fcl inhibit\u00f6rler geli\u015ftirilmektedir <strong>[doi:10.1038\/s41571-021-00516-7]<\/strong>.<\/p>\n<h2>Kaynaklar (DOI)<\/h2>\n<ul>\n<li>10.1056\/NEJMoa1917239<\/li>\n<li>10.1056\/NEJMp2106845<\/li>\n<li>10.1038\/s41586-020-2535-0<\/li>\n<li>10.1056\/NEJMoa2103695<\/li>\n<li>10.1016\/S1470-2045(21)00152-3<\/li>\n<li>10.1038\/s41571-021-00516-7<\/li>\n<li>10.1038\/s41586-021-04064-x<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Sotorasib, KRAS G12C mutasyonunu hedefleyen ilk k\u00fc\u00e7\u00fck molek\u00fcl inhibit\u00f6rlerinden biridir. NSCLC\u2019de ki\u015fiselle\u015ftirilmi\u015f tedavi, etki mekanizmas\u0131, klinik veriler ve FDA onay\u0131 ile akci\u011fer kanseri tedavisinde neden yeni bir d\u00f6nem ba\u015flat\u0131yor, detayl\u0131 inceleyin.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[122],"tags":[813,860,859,811,857,858,812],"class_list":["post-10312","post","type-post","status-publish","format-standard","hentry","category-molekul","tag-akciger-kanseri","tag-hedefe-yonelik-tedaviler","tag-kisisellestirilmis-onkoloji","tag-kras-g12c","tag-kucuk-molekul-hedefe-yonelik-tedavi","tag-nsclc","tag-sotorasib"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/posts\/10312","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=10312"}],"version-history":[{"count":1,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/posts\/10312\/revisions"}],"predecessor-version":[{"id":10313,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/posts\/10312\/revisions\/10313"}],"wp:attachment":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=10312"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=10312"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=10312"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}